Localized Immune Cascade Programming in Desmoplastic Tumors: In Silico Modeling and Validation Study

Abstract Background Despite the success of immune checkpoint inhibitors in certain cancers, many late-stage solid tumors remain “immune cold,” characterized by low T-cell infiltration, dense extracellular matrix (ECM), stromal and vascular barriers, and poor responses to systemic immunotherapy. Overcoming these resistance mechanisms requires localized and controlled reprogramming of the tumor microenvironment to permit effective antitumor immunity. Objective This strategy proposes a biomarker-guided, staged, and locally confined immune cascade designed to enable reinfiltration and activation of endogenous or autologous T cells in previously unresponsive solid tumors. Methods “Second Breath” involves a sequential intervention targeting physical and immunologic barriers. Local enzymatic matrix disruption using a collagenase-hyaluronidase mixture combined with lysyl oxidase inhibition reduces ECM density and stromal barriers. Transient recruitment and activation of innate immune cells are induced using weakly immunogenic bacteria or localized toll-like receptor agonists to generate local danger signals. Controlled, microdosed intratumoral cytokine pulses (IL-12, interferon γ [IFN-γ], tumor necrosis factor [TNF] α) amplify local antigen presentation and effector T-cell priming while minimizing systemic exposure. Optional autologous T-cell augmentation can be administered intratumorally or systemically during the window of heightened immune activation. A recovery or containment phase using local antibiotics or immunomodulators limits excessive inflammation and restores tissue homeostasis after bacteriotherapy. Candidate gene sets (≈80 genes) were mapped into protein-protein interaction networks using STRING version 11.5 and Cytoscape version 3.9.1. Hub analysis (degree >10) identified TNF, toll-like receptor 4 (TLR4), cytotoxic T-lymphocyte–associated protein 4 (CTLA4), signal transducer and activator of transcription 1, and CD274 as central regulators. Functional enrichment via DAVID version 2021 revealed significant involvement of the Wnt signaling pathway (Benjamini-adjusted P